Tech Company M&A Transactions
Ceptaris Therapeutics Acquisition
Ceptaris Therapeutics was acquired by Actelion. The transaction was announced on 8/1/2013. Actelion said the transaction price was $250 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/1/2013
Transaction Type
M&A
Amount
$250,000,000
M&A Terms
Actelion said it already paid Ceptaris $25 million (16.4 million pounds) and will pay another $225 million when the deal closes. The deal is contingent on Valchlor clinching approval from the U.S. health regulator.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Tullman
Chief Medical Officer
Jeffrey Wilkins
Chief Operating Officer
Douglas Gssl
VP - Bus. Development
Evan Dick
VP - General Counsel
Kamil Ali-Jackson
VP - Operations
Jeffrey Shaver
VP - R & D
Timothy Henkel
Browse more venture capital transactions:
Prev: 8/1/2013: Avant Healthcare venture capital transaction
Next: 8/1/2013: Mandalay Sports Media venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs